UY38075A - Composiciones anticonceptivas con efectos cardiovasculares reducidos - Google Patents

Composiciones anticonceptivas con efectos cardiovasculares reducidos

Info

Publication number
UY38075A
UY38075A UY38075A UY38075A UY38075A UY 38075 A UY38075 A UY 38075A UY 38075 A UY38075 A UY 38075A UY 38075 A UY38075 A UY 38075A UY 38075 A UY38075 A UY 38075A
Authority
UY
Uruguay
Prior art keywords
thromboembolism
cardiovascular effects
reduced
reduced risk
reduced cardiovascular
Prior art date
Application number
UY38075A
Other languages
English (en)
Spanish (es)
Inventor
Maud Jost
Glwadys Rausin
Original Assignee
Estetra Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Estetra Sprl filed Critical Estetra Sprl
Publication of UY38075A publication Critical patent/UY38075A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
UY38075A 2018-02-07 2019-02-07 Composiciones anticonceptivas con efectos cardiovasculares reducidos UY38075A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18155571 2018-02-07
EP18160586 2018-03-07

Publications (1)

Publication Number Publication Date
UY38075A true UY38075A (es) 2019-10-01

Family

ID=65278388

Family Applications (1)

Application Number Title Priority Date Filing Date
UY38075A UY38075A (es) 2018-02-07 2019-02-07 Composiciones anticonceptivas con efectos cardiovasculares reducidos

Country Status (20)

Country Link
EP (2) EP4140489A1 (https=)
JP (2) JP2021513507A (https=)
KR (1) KR102717921B1 (https=)
CN (2) CN115429806A (https=)
AU (1) AU2019219070B2 (https=)
CA (2) CA3178181A1 (https=)
CL (1) CL2020002017A1 (https=)
EC (1) ECSP20054822A (https=)
GE (2) GEAP202215414A (https=)
IL (1) IL276584B2 (https=)
JO (1) JOP20200169A1 (https=)
MA (1) MA51733A (https=)
NZ (1) NZ766027A (https=)
PH (1) PH12020500601A1 (https=)
PY (1) PY1908892A (https=)
SG (1) SG11202007163WA (https=)
TW (1) TWI845496B (https=)
UA (1) UA126746C2 (https=)
UY (1) UY38075A (https=)
WO (1) WO2019154899A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3701944T3 (da) 2015-06-18 2022-03-14 Estetra Srl Oro-dispergerbar doseringsenhed indeholdende en estetrolkomponent
LT3310346T (lt) 2015-06-18 2021-06-10 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
CR20180042A (es) 2015-06-18 2018-05-03 Mithra Pharmaceuticals S A Unidad de dosificación orodispersable que contiene un componente estetrol.
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
CN111989105B (zh) 2018-04-19 2024-07-19 埃斯特拉私人有限责任公司 化合物以及它们在缓解绝经相关症状中的用途
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
TWI893101B (zh) * 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
WO2022248733A1 (en) 2021-05-28 2022-12-01 Neuralis Sa Use of estetrol in treatment of respiratory infection diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4344405C2 (de) 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
EP1390042B1 (en) * 2001-05-23 2007-11-28 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
EP1535618A1 (en) * 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
CA2762640A1 (en) * 2009-05-22 2010-11-25 Stefanie Lindemann Medication for oral administration, comprising at least one estrogen and/or at least one gestagen and at least one probiotic bacterial strain
WO2012055840A1 (en) * 2010-10-28 2012-05-03 Bayer Pharma Aktiengesellschaft Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders
JP6447931B2 (ja) * 2013-12-12 2019-01-09 ドネスタ バイオサイエンス ビー.ブイ.Donesta Bioscience B.V. エステトロール成分を含有する口腔内崩壊固体単位剤形
CA3041016C (en) 2016-10-28 2023-09-05 Estetra Sprl Method for the management of dysmenorrhea and menstrual pain
KR102712911B1 (ko) * 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법

Also Published As

Publication number Publication date
JP2024009834A (ja) 2024-01-23
CN111683664A (zh) 2020-09-18
JOP20200169A1 (ar) 2020-07-07
IL276584B2 (en) 2024-10-01
CA3178181A1 (en) 2019-08-15
IL276584B1 (en) 2024-06-01
EP3749327A1 (en) 2020-12-16
AU2019219070B2 (en) 2024-12-19
TW202011967A (zh) 2020-04-01
SG11202007163WA (en) 2020-08-28
GEAP202215414A (en) 2022-04-25
ECSP20054822A (es) 2020-12-31
AU2019219070A1 (en) 2020-09-24
IL276584A (en) 2020-09-30
JP7651645B2 (ja) 2025-03-26
NZ766027A (en) 2026-03-27
GEP20227407B (en) 2022-08-25
PH12020500601A1 (en) 2021-05-17
CN115429806A (zh) 2022-12-06
WO2019154899A1 (en) 2019-08-15
KR20200118464A (ko) 2020-10-15
CA3089804A1 (en) 2019-08-15
MA51733A (fr) 2020-12-16
CL2020002017A1 (es) 2020-12-04
EP4140489A1 (en) 2023-03-01
PY1908892A (es) 2019-10-15
TWI845496B (zh) 2024-06-21
JP2021513507A (ja) 2021-05-27
UA126746C2 (uk) 2023-01-18
KR102717921B1 (ko) 2024-10-16

Similar Documents

Publication Publication Date Title
CL2020002017A1 (es) Composición anticonceptiva con efectos cardiovasculares reducidos.
MX2018011348A (es) Composiciones de extractos naturales y uso de los mismos para prevenir o tratar enfermedades.
MX2018008010A (es) Composicion y metodo para el crecimiento del pelo.
CL2020002252A1 (es) Formulación oftálmica.
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
CL2017002636A1 (es) Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
MX2019001298A (es) Metodo de manejo de dismenorrea y dolor menstrual.
MX2018010902A (es) Esteroides neuroactivos, composiciones y usos de los mismos.
MX2017003037A (es) Esteroides neuroactivos, composiciones y usos de los mismos.
CO2017011046A2 (es) Prenda absorbente con buen ajuste
MY205032A (en) Method for the management of dysmenorrhea and menstrual pain
MX2021005801A (es) Metodos para administrar corticosteroides.
CL2017001964A1 (es) Encapsulado de agentes activos de alta potencia.
CO2021005679A2 (es) Composiciones que comprenden celulosa oxidada
CO2020005366A2 (es) Composición plaguicida que contiene tidiazurón y ácido poliglutámico
CL2019000174A1 (es) Composición vaginal que comprende una combinación de estrógeno y vitamina d.
MX384303B (es) Composiciones y métodos para metabolismo muscular mejorado.
AR114357A1 (es) Composiciones anticonceptivas con efectos cardiovasculares reducidos
EA201891752A3 (ru) Фармацевтическая композиция для улучшения состояния при хронической почечной недостаточности или предотвращения ее прогрессирования
CO2020003134A2 (es) Moduladores de la expresión de enac
EA202091811A1 (ru) Композиция контрацептива со сниженными эффектами в отношении сердечно-сосудистой системы
BR112021015795A8 (pt) Composição
AR106690A1 (es) Método para administrar escualamina o una sal farmacéuticamente aceptable a la esclerótica posterior y a la coroides del ojo
AR117833A1 (es) Composición prebiótica y su uso

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20250211